Compare Amgen, Inc. (AMGN) vs Datadog Inc (DDOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Datadog Inc — how do they compare? Amgen, Inc. trades at $415.52 (market cap $224.14B), while Datadog Inc trades at $245.33 (market cap $88.61B). The key difference: Amgen, Inc. is far larger — about 2.5× Datadog Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| AMGN | DDOG | |
|---|---|---|
Market Cap | $224.14B | $88.61B |
Sector | Health | Technology |
52-Week High | $417.20 | $288.15 |
52-Week Low | $271.18 | $102.62 |
Enterprise Value | $267.45B | $84.90B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Datadog (DDOG) trades at $260.78, up 11.48% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations with EPS of $0.65 versus $0.583 estimated. Revenue grew 36% year-over-year, and the company raised full-year 2026 guidance. Technical indicators show a bullish trend with support at $239 and resistance at $272, while high valuation multiples like a P/E of 493.56 signal premium pricing. Recent news highlights AI-driven growth but also insider selling and market sensitivity to guidance nuances.
The outlook remains positive due to robust revenue growth and AI adoption, but risks include elevated valuations and customer concentration. Analyst consensus is strongly bullish with an average price target of $288.55, though investors should monitor execution against high expectations and competitive pressures in the cloud monitoring space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →
